Clinical Trial Update: A Phase 2 Study With IPI-926 in Patients With Myelofibrosis [Phase 2]

View source ↗

Summary

This entry notes the completion of a Phase 2 study of IPI-926 (saridegib) in patients with primary myelofibrosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• IPI-926 (IPI-926)

Snippet

Sponsor: Infinity Pharmaceuticals, Inc. | Conditions: Primary Myelofibrosis, Fibrosis, Bone Marrow | Phase 2 | Status: COMPLETED